SCHEMBL19874715

SCHEMBL19874715

Cn1c(=O)[nH]c(=O)c2c1nc(Nc1nc3ccccc3[nH]1)n2Cc1ccccc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TPH2 Q8IWU9 4/20 0.82
▸ TPH1 P17752 3/20 0.65
▸ BRAF P15056 3/20 0.62
▸ POLB P06746 3/20 0.60
▸ RAB9A P51151 2/20 0.60
▸ MEN1 O00255 2/20 0.60
▸ KMT2A Q03164 2/20 0.60
▸ GAA P10253 1/20 0.60
▸ CYP3A4 P08684 1/20 0.58
▸ CYP2C9 P11712 1/20 0.58
▸ PKM P14618 1/20 0.58
▸ CYP2C19 P33261 1/20 0.58
▸ MAPK1 P28482 2/20 0.55
▸ USP2 O75604 2/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ BRCA1 P38398 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ CXCL8 P10145 2/20 0.55
▸ NOD2 Q9HC29 2/20 0.55
▸ NOD1 Q9Y239 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19874657 0.90 TPH2 (0.85) TPH2TPH1BRAFPOLBRAB9A
SCHEMBL19874651 0.90 TPH2 (1.00) TPH2TPH1BRAFPOLBRAB9A
SCHEMBL18036490 0.79 TPH2 (1.00) TPH2TPH1MEN1KMT2A
SCHEMBL18036502 0.78 TPH2 (1.00) TPH2TPH1BRAFGAAPKM
SCHEMBL18036494 0.77 TPH1 (0.64) TPH2TPH1BRAFPOLBRAB9A
SCHEMBL555082 0.76 BRAF (0.72) TPH2TPH1BRAFPOLBRAB9A
SCHEMBL6348692 0.76 BRAF (0.72) TPH2TPH1BRAFPOLBRAB9A
SCHEMBL4667126 0.75 RECQL (0.76) BRAFPOLBRAB9AMEN1KMT2A
SCHEMBL18036499 0.71 TPH2 (1.00) TPH2TPH1BRAFGAAPKM
SCHEMBL18036521 0.70 TPH2 (0.78) TPH2TPH1BRAFPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3262044-B1 XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2019-02-06 — — EP disclosed
US-20180051025-A1 XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME Max-Delbrück-Centrum für Molekulare Medizin (DE) 2018-02-22 — — US disclosed
US-20180051025-A1 XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME Max-Delbrück-Centrum für Molekulare Medizin (DE) 2018-02-22 — — US disclosed
US-20180051025-A1 XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME Max-Delbrück-Centrum für Molekulare Medizin (DE) 2018-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180051025-A1 XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME TPH1, XDH, TPH2 TPH2 3/4885TPH1 1/4885BRAF 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback